Dechra Pharmaceuticals plc Receives Buy Rating from FinnCap (DPH)
Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “buy” rating restated by equities researchers at FinnCap in a research report issued on Wednesday, Analyst RN reports. They currently have a GBX 800 ($13.44) price objective on the stock. FinnCap’s price objective would suggest a potential upside of 12.85% from the company’s current price.
Shares of Dechra Pharmaceuticals plc (LON:DPH) traded up 2.59% during mid-day trading on Wednesday, hitting GBX 708.88. 212,895 shares of the company’s stock traded hands. Dechra Pharmaceuticals plc has a 52-week low of GBX 655.00 and a 52-week high of GBX 755.00. The stock has a 50-day moving average of GBX 676. and a 200-day moving average of GBX 688.1. The company’s market cap is £618.2 million.
A number of other analysts have also recently weighed in on DPH. Analysts at Investec reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Wednesday. They now have a GBX 787 ($13.22) price target on the stock. Separately, analysts at N+1 Singer raised their price target on shares of Dechra Pharmaceuticals plc from GBX 740 ($12.43) to GBX 760 ($12.77) in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of GBX 773.14 ($12.99).
Dechra Pharmaceuticals PLC (LON:DPH) is a holding company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.